Avidity Biosciences Inc

NASDAQ:RNAUnited States

Today

Show headlines and story abstract

• Avidity Biosciences Plans $300 Million Common Stock Offering, from 3 hours ago by MT Newswires

  3 hours ago by MT Newswires
  Companies Mentioned: RNA
  04:27 PM EDT, 06/12/2024 (MT Newswires) -- Avidity Biosciences (RNA) said Wednesday it intends to offer $300 million common shares in an underwritten public offering. The biopharmaceutical company intends to grant the underwriters a 30-day option to...

• Sector Update: Health Care Stocks Ease Late Afternoon, from 3 hours ago by MT Newswires

  3 hours ago by MT Newswires
  Companies Mentioned: PTN, MREO, RNA, RARE, CATX
  04:02 PM EDT, 06/12/2024 (MT Newswires) -- Health care stocks were softer late Wednesday afternoon, with the NYSE Health Care Index decreasing 0.3% and the Health Care Select Sector SPDR Fund (XLV) down 0.1%. The iShares Biotechnology ETF (IBB) rose...

• Avidity Biosciences, Inc. Announces Proposed Public Offering of Common Stock, from 3 hours ago by PR Newswire

  3 hours ago by PR Newswire
  Companies Mentioned: RNA

  Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that it intends to offer and sell, subject to market and other conditions, $300.0 million of shares of its common stock in an underwritten public offering. In addition, Avidity intends to grant the underwriters a 30-day option to purchase up to an additional $45.0 million of shares of common stock. All of the shares to be sold in the offering are to be sold by Avidity. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

• Avidity Biosciences, Inc. Announces Proposed Public Offering of Common Stock, from 3 hours ago by Dow Jones

  3 hours ago by Dow Jones
  Companies Mentioned: RNA
  
  Avidity Biosciences, Inc. Announces Proposed Public Offering of Common Stock
  
  PR Newswire
  
  SAN DIEGO, June 12, 2024
  
  SAN DIEGO, June 12, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs(TM)), today announced that it intends to offer and sell, subject to market and other conditions, $300.0 million of shares of its common stock in an underwritten public offering. In addition, Avidity intends to grant the underwriters a 30-day option to purchase up to an additional $45.0 million of shares of common stock. All of the shares to be sold in the offering are to be sold by Avidity. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
  

• DJ Avidity Biosciences Is Maintained at Buy by Needham, from 3 hours ago by Dow Jones

  3 hours ago by Dow Jones
  Companies Mentioned: RNA
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/RNA/analyst-ratings
  
  (END) Dow Jones Newswires
  
  June 12, 2024 15:45 ET (19:45 GMT)